AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.
Policy quality-scores-2: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 3/6 · 18/10/2026
Moat—
Insufficient evidence for every rubric criterion; no category score is inferred.
structural advantage · — · Patent coverage and commercial adoption establish proprietary assets, but their ability to exclude substitutes or sustain superior economics is unresolved.
durability · — · Patent expiration dates span many years, but economically critical rights and resistance to technological substitution are unidentified.
customer dependency · — · Consumables demand and platform migration support continued engagement, but do not establish customer dependence or material switching penalties.
erosion resilience · — · Demand recovery coexists with experienced pricing pressure and longer sales cycles. The passages cannot establish whether a structural advantage withstands this competition.
Pricing power44
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
realized pricing · 1/4 · Experienced competitive pricing pressure is direct evidence of fragile pricing. Partial tariff mitigation through pricing actions provides an offset, but its contribution is unquantified and no realized price trend is supplied.
retention · 2/4 · Continued consumables demand, substantial migration to NovaSeq X and firm remaining obligations support repeat engagement indirectly. They do not identify same-customer retention, switching costs or customer losses, and competition has lengthened sales cycles.
margin resilience · 2/4 · YTD 2026 operating margin improved despite headwinds, but gross margin declined excluding the prior-year impairment effect. Cost measures and mix influence these outcomes, so resilience cannot be attributed solely to pricing.
contractual freedom · 2/4 · Implemented pricing actions demonstrate some practical discretion, and most performance obligations are satisfied within about six months. Development and licensing arrangements permit early termination with prorated fees. These provide mixed evidence of flexibility, without establishing unilateral repricing rights.
Predictability75
Five consecutive annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.
- Nondeclining revenue years (%)
- 25.00
- Revenue growth volatility (pp)
- 1.55
- Positive FCF years (%)
- 100.00
- FCF margin volatility (pp)
- 7.02
Financial strength—
Missing required inputs: debtFcfGrade, netDebtEbitGrade. Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, or reported pretax profit plus reported interest expense when operating income is unavailable. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.
- interestCoverageGrade
- 63.55
- currentRatioGrade
- 100.00
- Interest coverage (x)
- 7.99
- Current ratio (x)
- 2.08
Capital allocation—
Missing required inputs: operatingReturn. Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income or, if unavailable, EBIT calculated from reported pretax profit plus reported interest expense; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. Nonpositive invested capital has no defined return and remains unavailable. Does not establish acquisition quality or buyback timing.
- 3-year average dilution (%)
- -1.33
- 3-year average SBC / revenue (%)
- 7.74
- cashConversionGrade
- 0.00
Management50
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
capital discipline · 2/4 · First-half 2026 operating cash generation of $490 million exceeded $78 million of capital expenditure, but acquisitions, intangible purchases and repurchases contributed to a $378 million cash decline. Historical impairments temper confidence in allocation outcomes; returns on recent acquisitions remain unproven.
incentive alignment · 2/4 · Actual 2025 equity grants were predominantly PSUs, with three-year relative TSR and operating-margin measures. Reported incentive achievement was below target, and salary increases and equity awards were reduced. Alignment is tempered by adjusted profit measures and qualifying change-in-control vesting at target; individual ownership is not established.
execution · 2/4 · Platform adoption and YTD 2026 revenue and operating-margin gains demonstrate execution through indirect operating evidence. Flat 2025 core revenue, below-target incentive performance and continuing competitive friction make the record mixed rather than consistently strong.
governance · 2/4 · Annual director elections, independent committees and actual independent-director sessions demonstrate governance mechanisms. Continuing GRAIL-related shareholder demands and board deferrals leave oversight effectiveness unresolved. Litigation allegations are not treated as adjudicated misconduct.
Evidence
Our issued and pending patents cover various aspects of our arrays, assays, oligo synthesis, sequencing technology, instruments, digital microfluidics, software, bioinformatics, and chemical-detection technologies, and our issued patents have terms that expire between 2025 and 2049.
Business / patent coverage and expiration terms · Filed 12/02/2025
We are party to various exclusive and nonexclusive license agreements and other arrangements with third parties that grant us rights to use key aspects of our sequencing and array technologies, assay methods, chemical detection methods, reagent kits, and scanning equipment.
Business / exclusive and nonexclusive technology licenses · Filed 12/02/2026
Customer adoption remained strong in the third year of the NovaSeq X rollout, with Illumina converting more than 70% of sequencing volume to the platform.
Chair's letter / NovaSeq X sequencing-volume adoption · Filed 09/04/2026
Consumables revenue increased primarily due to demand for high-throughput consumables, partially offset by decreased service and other revenue, primarily due to decreased revenue from our strategic partnerships, and a decrease in instruments revenue, primarily due to fewer shipments of our high- and mid-throughput sequencing instruments.
MD&A / 2025 consumables demand and instrument shipments · Filed 12/02/2026
Financial highlights for YTD 2026 included the following: •Revenue increased 7% in YTD 2026 to $2,251 million compared to $2,100 million in YTD 2025 primarily due to increases in consumables and instruments related to demand for our NovaSeq X instrument.
MD&A / YTD 2026 revenue and NovaSeq X demand · Filed 31/07/2026
We have faced, and expect to continue to face, increased pricing pressure from competitors who offer sequencing products and we have experienced lengthened sales cycles with many customers due to competition.
Risk Factors / experienced pricing pressure and longer sales cycles · Filed 12/02/2026
For example, complementary third-party sequencing technologies address use cases to which our products are not as well suited.
Risk Factors / applications better served by complementary technologies · Filed 12/02/2026
Pursuant to the terms of the Agreement, we agreed to pay CGI a one time payment of $325 million.
Legal Proceedings / historical settlement payment obligation · Filed 16/02/2024
We allocated the $325 million payment on a relative fair value basis, resulting in $180 million capitalized as an intangible asset in 2022 for the value of the license, which is amortized over a period of 6.5 years on a straight-line basis, $150 million allocated to the release of past damages claimed, and a $5 million gain for damages awarded to us.
Legal Proceedings / allocation of settlement payment to licensing and damages · Filed 16/02/2024
We have partially mitigated the effects of tariffs through supply-chain optimization, cost measures, and pricing actions, and aim to continue such efforts in the future.
MD&A / partial tariff mitigation through cost, supply-chain and pricing actions · Filed 31/07/2026
Revenue increased 7% to $2,251 million and operating margin increased to 20.2% in YTD 2026 as compared to 18.0% in YTD 2025.
MD&A / YTD 2026 revenue and operating-margin improvement · Filed 31/07/2026
Excluding this impact, gross margin decreased primarily due to higher tariff costs, increased sales mix toward lower-margin instruments as compared to higher-margin consumables, the addition of lower-margin SomaLogic revenue, and higher memory chip and freight costs, partially offset by decreases for field service and warranty costs.
MD&A / underlying gross-margin decline and cost drivers · Filed 31/07/2026
Most performance obligations are generally satisfied within approximately six months after the contract execution date and primarily consist of instruments, consumables, and instrument service contracts.
Revenue note / typical performance-obligation duration · Filed 31/07/2026
As of June 28, 2026, the aggregate amount of the transaction price allocated to these remaining performance obligations was $1.0 billion, of which approximately 83% is expected to be converted to revenue in the next twelve months, approximately 11% in the following twelve months, and the remainder thereafter.
Revenue note / remaining performance obligations · Filed 31/07/2026
These contracts are believed to be firm as of the balance sheet date; however, these arrangements do allow for early termination with prorated fees.
Revenue note / development and licensing contract termination provisions · Filed 31/07/2026
9 Table of Contents ILLUMINA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In millions) Six Months Ended June 28, 2026 June 29, 2025 Cash flows from operating activities: Net income $ 340 $ 366 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation expense 102 103 Amortization of intangible assets 37 34 Share-based compensation expense 133 142 Deferred income taxes 18 41 Net losses (gains) on investments 16 (133) Change in fair value of contingent consideration liabilities (32) (32) Intangible impairment — 23 Other 4 9 Changes in operating assets and liabilities: Accounts receivable 92 49 Inventory (31) (28) Prepaid expenses and other current assets (9) 11 Operating lease right-of-use assets and liabilities, net (18) (17) Other assets (72) (3) Accounts payable (2) (26) Accrued liabilities (24) (91) Other long-term liabilities (64) 26 Net cash provided by operating activities 490 474 Cash flows from investing activities: Net purchases of property and equipment (78) (62) Net sales (purchases) of investments 32 (43) Cash paid for acquisitions and intangible assets, net of cash acquired (417) (7) Payments on contingent consideration liabilities (25) — Net cash used in investing activities (488) (112) Cash flows from financing activities: Common stock repurchases, inclusive of excise tax (370) (570) Taxes paid related to net share settlement of equity awards (33) (23) Proceeds from issuance of common stock 24 28 Payments on contingent consideration liabilities (1) (1) Net cash used in financing activities (380) (566) Effect of exchange rate changes on cash and cash equivalents — 11 Net decrease in cash and cash equivalents (378) (193) Cash and cash equivalents at beginning of period 1,418 1,127 Cash and cash equivalents at end of period $ 1,040 $ 934 See accompanying notes to condensed consolidated financial statements.
Condensed consolidated statements of cash flows / first-half 2026 spending and cash generation · Filed 31/07/2026
The primary adjustments to net loss included goodwill and intangible impairment of $1,889 million, share-based compensation expense of $370 million, depreciation and amortization expense of $354 million, net loss on strategic investments of $312 million, and property and equipment and right-of-use asset impairment of $46 million, offset by change in fair value of contingent consideration liabilities of $315 million and deferred income taxes of $112 million.
MD&A / 2024 impairment and other noncash adjustments · Filed 12/02/2025
Performance Stock Units (PSUs) PSUs vest and are earned based on 3-year Company Relative TSR performance against select companies in the Nasdaq Biotechnology Index and 3-year average achievement of pre-determined operating margin targets at the end of the 3-year period.
Executive compensation / three-year PSU performance measures · Filed 09/04/2026
Performance Stock Units represent approximately 70% of the overall grant value.
Fiscal 2025 long-term equity compensation / awarded PSU proportion · Filed 09/04/2026
Performance Goals (in $ millions) Metric (Weight) Threshold Target Maximum Actual % Achievement Revenue (50%) 4,194 4,410 4,691 4,356 88% Payout as a % of Target 50% 100% 200% Non-GAAP operating income(1) (50%) 1,213 1,367 1,522 1,298 66% Payout as a % of Target 25% 100% 200% 2025 Achievement 77% (1) Non-GAAP operating income is a non-GAAP measure, used for VCP purposes, and consists of income (loss) from operations, adjusted for changes in FX, amortization of acquired intangible assets, acquisition-related expenses, legal contingencies and settlements, changes in contingent consideration liabilities, restructuring charges and stock-based compensation expense.
Executive compensation / actual 2025 incentive performance · Filed 09/04/2026
The Compensation Committee and Board approved both the suspension of the salary increases and the reduction of annual equity awards.
Executive compensation / approved salary freeze and equity-award reduction · Filed 09/04/2026
Thaysen); • automatic vesting of the executive’s unvested equity or equity-based awards at 100% achievement; and • certain professional outplacement services consistent with the executive’s position for up to two years following termination.
Change-in-control severance / equity vesting provision · Filed 09/04/2026
All our directors stand for election to one-year terms.
Corporate governance / annual director elections · Filed 09/04/2026
At its meetings during the fiscal year ended December 28, 2025 (“fiscal 2025”), the Board of Directors regularly met in executive sessions of non-employee, independent directors.
Corporate governance / independent-director executive sessions during fiscal 2025 · Filed 09/04/2026
All of the standing Board committees are composed solely of non-employee, independent directors.
Corporate governance / independent standing committees · Filed 09/04/2026
On February 4, 2026, the Board unanimously determined that it was in the best interest of the Company and its shareholders to continue to defer a final decision on the demand.
Legal Proceedings / February 2026 board deferral of shareholder demand · Filed 31/07/2026
Like the complaints described above, the lawsuits allege the named directors and officers breached their fiduciary duties by knowingly causing Illumina to unlawfully close the GRAIL acquisition.
Legal Proceedings / allegations concerning the GRAIL acquisition · Filed 31/07/2026
34 Financial highlights for 2025 included the following: •Core Illumina revenue was $4.34 billion in 2025 and relatively flat compared to revenue of $4.33 billion in 2024.
MD&A / flat 2025 Core Illumina revenue · Filed 12/02/2026
